We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers spent $155 million lobbying Congress between January 2005 and June 2006, trying to influence legislation on Medicare, drug importation and patent protection, according to a study by The Center for Public Integrity.
U.S. Senator Chris Dodd (D-Conn.) reintroduced a bill to improve incentives for developing pediatric medical devices so that children are not left with “one-size-fits-all” products, his office announced in mid-March.
As part of a Senate Finance Committee investigation, Sen. Chuck Grassley (R-Iowa) is requesting information from Eli Lilly regarding the marketing of its antipsychotic drug Zyprexa.
As advocates of bipartisan legislation aimed at lowering Medicare drug prices through direct government negotiation stepped up their efforts to garner support, some in the pharmaceutical industry believe such a policy shift would limit access to certain drugs under the government program.
Two leading House members sent a letter to FDA Commissioner Andrew von Eschenbach asking him when he would have to alert agency employees about possible layoffs if the Prescription Drug User Fee Act (PDUFA) is not reauthorized.
The Senate should pattern its Medicare prescription drug bill after an earlier version introduced in the House that would let the federal government pursue lower drug costs through direct negotiation with drug companies, Sen. Debbie Stabenow (D-Mich.) said.
Biotechnology industry leaders are telling House lawmakers that proposed legislation allowing the FDA to approve follow-on biologics should include clear and sound patient safety provisions.
House Oversight and Reform Committee Chairman Henry Waxman (D-Calif.) has taken an interest in the debate over how
the FDA can approve follow-on biologics, holding a hearing on
the issue featuring scientists from the pharmaceutical industry.
Two leading House lawmakers are investigating FDA Commissioner Andrew von Eschenbach’s recent testimony on Ketek over concerns that he may have “intentionally misled” a subcommittee about the drug’s approval process.
Faced with soaring healthcare costs driven in part by biopharmaceutical therapies, federal policymakers should give the FDA power to approve follow-on biologics, AARP said.